SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is trending downward following a significant post-earnings sell-off driven by weak future sales guidance and concerns over the company's turnaround progress in key international markets. The investor community remains sharply divided, with some actively buying the dip as a long-term value play, while others criticize the brand's loss of cultural relevance and competitive positioning against emerging sportswear rivals.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending as investors weigh recent capital allocation moves, including a multi-billion dollar stake repurchase in its Irish manufacturing site, against broader market volatility and geopolitical concerns affecting the semiconductor sector. While the community remains divided between long-term bulls highlighting foundry expansion and AI growth and short-term bears skeptical of manufacturing headwinds, active discussion is dominated by the stock's pronounced intraday volatility and its sensitivity to macroeconomic headlines.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors react to the company's fiscal Q3 earnings report, which highlighted record revenue and international growth, though community sentiment remains polarized over management and the stock's long-term performance. While some participants are betting on an upside reversal tied to broader cannabis sector catalysts and rescheduling prospects, others remain skeptical, citing concerns over dilution and historical share price declines.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating significant buzz as investors track positive Phase 3 clinical data for its lead skin disease treatment, sonelokimab, while speculating on the potential for a high-premium buyout. The community remains deeply divided, with some retail investors holding for generational wealth based on clinical performance while others warn of price manipulation, short-selling pressure, and the impact of institutional divestments.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors focus on the commercial launch of YARTEMLEA, with the community closely tracking initial patient uptake, formulary approvals at major transplant centers, and the company's timeline for reaching positive cash flow. While the stock has faced downward pressure due to technical factors and broader market volatility, discussions are heavily centered on upcoming Q1 sales updates, the potential for milestone payments from the Novo Nordisk partnership, and imminent EU regulatory milestones.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is currently experiencing intense volatility following a significant earnings miss and lowered guidance, with the stock drawing heavy attention due to its massive short interest and the ongoing debate over whether it is a value play or a potential bankruptcy candidate. The community is sharply divided, with bulls betting on a short squeeze and long-term luxury market recovery, while bears point to persistent housing market headwinds, tariff-related margin compression, and expensive international expansion as signs of long-term deterioration.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is experiencing heightened investor interest following the announcement of a massive multi-year AI cloud infrastructure agreement, which has sparked intense debate over the stock's potential for a significant short squeeze. Community members are actively discussing the company's low float and the strategic impact of this contract, leading to speculation about aggressive price moves while some remain cautious of potential spoofing and market volatility.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the upcoming 10-K filing and earnings report, with community members closely tracking the company's aggressive debt reduction efforts and the performance of key holdings like Applied Digital and BW. Bullish participants are actively discussing a potential valuation re-rating and the possibility of a short squeeze, while keeping a watchful eye on management's next steps to address previous legal overhangs and restore institutional confidence.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors monitor ongoing project developments, including the upcoming pilot plant operations and the status of the Definitive Feasibility Study. Market participants are actively debating the stock's valuation relative to its rare earth assets while navigating volatility driven by broader sector trends and geopolitical developments.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant volatility as investors debate the impact of potential memory compression technologies on future demand versus strong long-term AI-driven storage needs. The community remains deeply divided, with some traders actively shorting into the price swings while others emphasize valuation metrics and anticipate a rebound leading up to upcoming quarterly earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned an average rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat.com reports. One...

HC Wainwright Issues Positive Forecast for LENZ Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for LENZ Therapeutics in a report issued on...

Citigroup Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price

Citigroup decreased their price objective on shares of LENZ Therapeutics from $52.00 to $26.00 and set a "buy" rating for the company in a report on Thursday...

FY2028 EPS Forecast for LENZ Therapeutics Lowered by Analyst

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for LENZ Therapeutics in a research note issued on Wednesday, March 25th. HC Wainwright analyst M. Caufield now anticipates that the company will earn $0.62 per share for the y...

Bank of America Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price

Bank of America decreased their target price on shares of LENZ Therapeutics from $35.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday...

LENZ Therapeutics (NASDAQ:LENZ) Posts Earnings Results, Misses Expectations By $0.25 EPS

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) posted its earnings results on Tuesday. The company reported ($1.16) EPS for the quarter, missing analysts' consensus estimates of ($0.91) by...

LENZ Therapeutics Q4 Earnings Call Highlights

Executives from LENZ Therapeutics (NASDAQ:LENZ) used the company's latest earnings call to provide an update on the early U.S. launch of its presbyopia eye drop, emphasizing initial physician...

LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -28.18% and -66.75%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings

LENZ Therapeutics (NASDAQ:LENZ) to release Q4 earnings on 3/24. Analysts expect loss of 90 cents/share. Stock gained 5% on Monday. Analyst ratings and accuracy rates available on Benzinga.read more...

LENZ Therapeutics (NASDAQ:LENZ) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen lowered shares of LENZ Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.

LENZ Therapeutics Inc.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Current Price	$9.73
Prev Close	$9.15
Open	$9.23
Dividend Yield	0.00%
50-Day Moving Average	$13.48
Beta	1.48
Avg. Volume	847,515.98
PE Ratio	-3.26

52-Week High	$50.40
52-Week Low	$8.25
Market Capitalization	$286.89M
EPS (Annual)	-$2.85
Price to Book	1.01
Revenue Per Employee	$125,578.95

LENZ
LENZ Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LENZ News

LENZLENZ Therapeutics Inc.